Bristol Myers Squibb's Zynexertus More Than Doubles Progression-Free Survival in Multiple Myeloma Phase 3 Trial
- 1Bristol Myers Squibb's Zynexertus (iverdomide) showed a median progression-free survival of 42 months in multiple myeloma patients.
- 2Zynexertus met the second primary endpoint of the clinical trial, recording a 51% reduction in the risk of disease progression or death.
- 3The drug demonstrated clinical value in a market projected to reach $29 billion by 2032 for multiple myeloma.
So what's the key point?
Bristol Myers Squibb's Zynexertus more than doubled the time cancer patients lived without their disease getting worse. It proved its value in a market expected to grow to $29 billion.
Source Clinical Trials Arena · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.